Compare PulteGroup, Inc. (PHM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs TransMedics Group Inc — how do they compare? PulteGroup, Inc. trades at $118.95 (market cap $22.87B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: PulteGroup, Inc. is far larger — about 7.5× TransMedics Group Inc's market cap, and PulteGroup, Inc. pays a 0.87% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PHM | TMDX | |
|---|---|---|
Market Cap | $22.87B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $142.56 | $150.42 |
52-Week Low | $110.11 | $61.99 |
Enterprise Value | $23.28B | $3.46B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.
The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
